Our client, a world leader in developing treatments for rare genetic diseases, is seeking novel therapeutic approaches to treat the underlying causes of genetic kidney disease. Specifically, our client is interested in solutions to treat autosomal dominant polycystic kidney disease (ADPKD) and Alport syndrome, as well as cystinuria and UMOD-associated chronic kidney disease (CKD).
Approaches to treat other rare genetic kidney diseases may also be of interest provided there is high unmet need, and the solution targets the underlying mechanisms of disease.
Approaches of Interest:
All modalities are of interest, with a preference for small molecules, oligonucleotides, peptides, AAV/gene therapy and biologics. Unique therapeutic modalities are encouraged. Approaches should address the core mechanisms of disease (E.g., correcting the genetic cause, or the central pathway of disease), not the associated symptoms.
Out of Scope:
Developmental Stages of Interest:
Submission Information and Opportunity for Collaboration
Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. The team encourages including the proposed next steps in developing the research towards commercialization. In submitting to this campaign, you confirm that your submission contains only non-confidential information.
Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include funded research collaborations and agreements, or licencing of assets.
Technology
Academic Researcher
Centre of Excellence
Research Project
Spinout Company
Biotech Asset
Technology
Academic Researcher
Centre of Excellence
Research Project
Spinout Company
Biotech Asset
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.